Diseases & Longevity · File 32

Inflammatory bowel disease. Chronic autoimmune — the systemic cluster defines longevity.

Inflammatory bowel disease (IBD) — Crohn's disease and ulcerative colitis — are chronic autoimmunes with predominantly intestinal involvement but significant systemic cluster: added CV risk from chronic inflammation, sarcopenia, nutritional deficits (Fe, B12, vitamin D), secondary osteoporosis, affected mental health. Modern biologics transformed prognosis. Longevity medicine operates on the systemic cluster, complementing gastroenterology.

Why IBD is systemic disease in addition to intestinal

TBD was classically taught as "intestinal disease" — but its biology is systemic. Chronic autoimmune inflammation produces persistent inflammaging with elevation of cytokines, hsCRP, serum calprotectin, and other mediators. That impacts multiple biological axes outside the intestine: accelerated atherosclerosis, inflammatory sarcopenia, secondary osteoporosis, chronic disease anemia, coexisting depression and anxiety.

Modern biologics (anti-TNF: infliximab, adalimumab; anti-IL12/23: ustekinumab; anti-α4β7-integrin: vedolizumab; JAK-i: tofacitinib, upadacitinib) have transformed prognosis when titrated to target (treat-to-target, ECCO 2022). But the decision, monitoring, and management of specific comorbidities (colorectal cancer screening by colonoscopy, fistula management, abscesses, surgery) belong to gastroenterology. Longevity medicine operates on the systemic cluster.

IBD is not just intestinal — it's systemic inflammatory disease with nutritional, bone, CV, and mental cluster. That reading changes longevity management.
People with IBD · global

The global weight, in numbers

Data come from GBD, ECCO, AGA, and comorbidity meta-analyses. They reflect the magnitude of the systemic cluster.

  • Global prevalence

    ~7M personas

    Approximately 7 million people live with IBD globally. Higher prevalence in HICs but rapid growth in LATAM and Asia. Peak presentation in young adults (20-40).
    — Ng et al., Lancet 2017

  • Sarcopenia in IBD

    ~40% pacientes activos

    Up to 40% of patients with active or moderate-severe IBD have sarcopenia. Independent predictor of surgical complications, hospitalization, and worse biologic outcome. Nutritional management and exercise are essential.
    — Bryant et al., Aliment Pharmacol Ther 2015

  • Added CV risk

    Inflammaging sostenido

    IBD is associated with higher cardiovascular event risk — particularly in patients with sustained activity — due to inflammaging and endothelial dysfunction. Added CV risk management is part of modern standard.
    — Singh et al., Aliment Pharmacol Ther 2014

  • Biologics transformed prognosis

    Treat-to-target ECCO 2022

    Biologics anti-TNF, anti-IL12/23 (ustekinumab), anti-integrin (vedolizumab), and JAK-i (tofacitinib, upadacitinib) have transformed moderate-severe IBD prognosis. ECCO 2022 confirms treat-to-target as standard.
    — Raine et al., J Crohn's Colitis 2022

Chap. 03 · Amplified systemic

The systemic cluster that longevity medicine complements

Gastroenterology controls intestinal activity. The systemic cluster — nutrition, bone health, CV risk, sarcopenia, mental health — is where longevity complements.

  • Nutritional deficits

    Fe, B12, vit D, calcio, zinc

    IBD frequently presents with deficits: iron (anemia), B12 (particularly Crohn's with ileal involvement), vitamin D, calcium, zinc, folate. Their systematic identification and correction is integral to management. Periodic monitoring is standard.
    — Massironi et al., Clin Nutr 2013

  • Secondary osteoporosis

    Cribado DEXA

    Chronic inflammation + corticosteroid use + vitamin D deficiency + sarcopenia increase osteoporosis risk in IBD. DEXA screening, vitamin D, calcium, strength exercise, and specific management when indicated. Endocrinology coordination.
    — Bernstein et al., Inflamm Bowel Dis 2018

  • Depression and anxiety

    ~30% comorbilidad

    Clinical depression and anxiety coexist in approximately 30% of IBD patients — particularly in sustained activity. They affect adherence, quality of life, and outcome. Structured support is integral.
    — Mikocka-Walus et al., Inflamm Bowel Dis 2016

  • Colorectal cancer risk

    Cribado colonoscópico

    Long-duration IBD (>8-10 years, particularly extensive ulcerative colitis) increases colorectal cancer risk. Periodic colonoscopic screening is standard — every 1-2 years in high risk. Gastroenterology decision.
    — ECCO/ESGE Guideline 2019

What we don't offer — and what we do

Wellness Care does not prescribe biologics, JAK-i, or immunomodulators. Choice of anti-TNF, ustekinumab, vedolizumab, JAK-i, adjustment per therapeutic serum levels, activity monitoring with fecal calprotectin or colonoscopy, colorectal cancer screening, and surgical decisions (resection, ostomy) belong exclusively to gastroenterology. What we do: integrated evaluation of the systemic cluster.

We evaluate patients with diagnosed IBD under gastroenterology management who have: nutritional deficits not systematically addressed, sarcopenia, suspected secondary osteoporosis, unmanaged added CV risk, coexisting depression / anxiety, or want to optimize the systemic longevity view. Coordination with gastroenterology, endocrinology, mental health, and other specialists always when indicated.

IBD requires gastroenterology. But the systemic cluster — nutrition, bone, CV, sarcopenia, mental — requires longevity view. That coordination changes real trajectory.
How we measure it

How the systemic cluster
of IBD is addressed

Nutrition + bone health + added CV risk + sarcopenia + mental health + microbiota. In gastroenterology coordination always.

Advanced biomarkers

21 specialized panels across 8 clinical categories — biological age, inflammaging, metabolic profile, functional hormonal, microbiota. The quantitative layer.

Explore →

Functional medicine

Shared root causes — mitochondrial dysfunction, inflammaging, neuroendocrine dysregulation — before organ pathology.

Explore →

Bioregulatory medicine

Autonomic regulation, HRV, stress response. The functional trajectory that precedes clinical diagnosis.

Explore →

The Longevity Program

How this assessment integrates into the full program — from initial valuation to individualized protocol design under medical judgment.

Explore →
Featured evidence

Key evidence supporting this approach

Four publications — global epidemiology, sarcopenia in IBD, added CV risk, ECCO 2022 treat-to-target.

«Aproximadamente 7 millones de personas viven con EII a nivel global. La incidencia crece rápidamente en LATAM y Asia.»
Lancet · 2017
Ng et al., Lancet 2017
Epidemiología global EII
«La sarcopenia afecta hasta el 40% de los pacientes con EII activa y es predictor independiente de complicaciones y peor desenlace.»
Aliment Pharmacol Ther · 2015
Bryant et al., 2015
Sarcopenia en EII
«ECCO 2022 confirma treat-to-target como estándar — el control sostenido de actividad inflamatoria es la diana central del manejo moderno.»
J Crohn's Colitis · 2022
Raine et al., 2022
ECCO Treat-to-target

Frequently asked questions about inflammatory bowel disease

The most recurrent questions about IBD — nutritional deficits, sarcopenia, secondary osteoporosis, and why longevity medicine complements gastroenterology.

01

What nutritional deficits are frequent in IBD?

Frequent and to monitor:

· Iron — iron deficiency anemia (particularly UC)
· Vitamin B12 — Crohn's with ileal involvement or resection
· Vitamin D — frequent, associated with osteoporosis
· Calcium — dietary deficit + corticosteroids
· Folate
· Zinc, magnesium
· Fat-soluble vitamins (A, E, K) — in severe malabsorption

Structured periodic screening and targeted supplementation are standard.

02

Does sarcopenia really matter in IBD?

Significantly.

Up to 40% of patients with active IBD have sarcopenia — independent predictor of:

· Surgical complications
· Worse response to biologics
· More hospitalization
· Worse quality of life

Essential integrated management:

· Adequate protein
· Adapted progressive strength training
· Nutritional optimization

Coordination with clinical nutrition and physiatry.

03

Is gut microbiota relevant in IBD?

Yes — and it's an active research area.

Microbial dysbiosis is characteristic in IBD:

· Reduced diversity
· Altered proportions (Firmicutes/Bacteroidetes)
· Reduced butyrate producers

Specific interventions with heterogeneous evidence:

· Select probiotics
· Elimination diet
· Fecal microbiota transplant (FMT)

For now, formal recommendations are limited — but the field evolves rapidly.

Informed decision with gastroenterology.

04

When should I consult?

An integrated assessment is worthwhile if:

· Diagnosed IBD under gastroenterology management but nutritional deficits not systematically addressed
· Sarcopenia
· Suspected secondary osteoporosis
· Unmanaged added CV risk
· Coexisting depression / anxiety
· Want to optimize the systemic longevity view

The assessment complements gastroenterology — does not replace it.

Beyond the intestine

IBD is not just intestinal — it's systemic inflammatory disease with nutritional, bone, CV, and mental cluster.

Individualized nutrition, bone screening, added CV risk, sarcopenia, and mental health — all in gastroenterology coordination. That integration changes trajectory.

Diagnosed IBD with systemic comorbidities?

Book a longevity assessment with IBD

We evaluate nutritional profile (Fe, ferritin, B12, vitamin D, calcium, zinc), body composition and sarcopenia, bone health (DEXA), added cardiovascular risk from inflammaging, mental health, and gut microbiota. Does not replace gastroenterology — complements it with the systemic view.

Book comprehensive assessment with IBD